{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:48:25Z","timestamp":1782488905645,"version":"3.54.5"},"reference-count":26,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T00:00:00Z","timestamp":1599523200000},"content-version":"unspecified","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014421","name":"EA Pharma Co., Ltd","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014421","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2020,7,8]]},"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Non-alcoholic fatty liver disease (NAFLD) pathogenesis involves abnormal metabolism of cholesterol and hepatic accumulation of toxic free-cholesterol. Elobixibat (EXB) inhibits the ileal bile acid (BA) transporter. EXB and cholestyramine (CTM) facilitate the removal of free cholesterol from the liver by decreasing BA recirculation to the liver, thereby stimulating novel BA synthesis from cholesterol. In this randomised, double-blind, placebo-controlled, parallel-group, phase IIa study, we aim to provide a proof-of-concept assessment by evaluating the efficacy and safety of EXB in combination with CTM in patients with NAFLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>A total of 100 adult patients with NAFLD, diagnosed based on low-density lipoprotein cholesterol (LDL-C) level of &gt;120 mg\/dL and liver fat content of \u22658% by MRI-based proton density fat fraction (MRI-PDFF), who meet the inclusion\/exclusion criteria will be enrolled. The patients will be randomly assigned to receive the combination therapy of 10 mg EXB and 9 g CTM powder (4 g CTM), 10 mg EXB monotherapy, 9 g CTM powder monotherapy or a placebo treatment (n=25 per group). Blood tests and MRIs will be performed 16 weeks following treatment initiation. The primary study endpoint will be the absolute LDL-C level change at week 16 after treatment initiation. The exploratory endpoint will include absolute changes in the liver fat fraction as measured by MRI-PDFF. This proof-of-concept study will determine whether the combination therapy of EXB and CTM is effective and safe for patients with NAFLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethics approval was obtained from the Ethics Committee of Yokohama City University Hospital before participant enrolment. The results of this study will be submitted for publication in international peer-reviewed journals and the key findings will be presented at international scientific conferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04235205\">NCT04235205<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2020-037961","type":"journal-article","created":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T13:04:24Z","timestamp":1599656664000},"page":"e037961","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct04235205","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02913105","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02927314","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5587-1386","authenticated-orcid":false,"given":"Takaomi","family":"Kessoku","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan"},{"name":"Department of Palliative Medicine, Yokohama City University Hospital, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ozaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiro","family":"Iwaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Honda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan"},{"name":"Department of Palliative Medicine, Yokohama City University Hospital, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kento","family":"Imajo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Saigusa","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Yokohama City University Graduate School of Medicine, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Yokohama City University Graduate School of Medicine, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeharu","family":"Yamanaka","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Yokohama City University Graduate School of Medicine, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Usuda","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Shimane University Faculty of Medicine Graduate School of Medicine, Izumo, Shimane, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Wada","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Shimane University Faculty of Medicine Graduate School of Medicine, Izumo, Shimane, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Yoneda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6263-1436","authenticated-orcid":false,"given":"Atsushi","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,9,9]]},"reference":[{"key":"2026062608012162000_10.9.e037961.1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-012-0533-z"},{"key":"2026062608012162000_10.9.e037961.2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.05.041"},{"key":"2026062608012162000_10.9.e037961.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.plipres.2012.11.002"},{"key":"2026062608012162000_10.9.e037961.4","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-015-3776-8"},{"key":"2026062608012162000_10.9.e037961.5","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e3282f4710a"},{"key":"2026062608012162000_10.9.e037961.6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29359"},{"key":"2026062608012162000_10.9.e037961.7","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S2468-1253(18)30123-7","article-title":"Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial","volume":"3","author":"Nakajima","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026062608012162000_10.9.e037961.8","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1111\/bcp.13698","article-title":"Effect of single and multiple doses of elobixibat, an ileal bile acid transporter inhibitor, on chronic constipation: a randomized controlled trial","volume":"84","author":"Kumagai","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"2026062608012162000_10.9.e037961.9","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf4823"},{"key":"2026062608012162000_10.9.e037961.10","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0016-5085(67)80140-9","article-title":"The syndrome of ileal disease and the broken enterohepatic circulation: cholerheic enteropathy","volume":"52","author":"Hofmann","year":"1967","journal-title":"Gastroenterology"},{"key":"2026062608012162000_10.9.e037961.11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2004.04139.x"},{"key":"2026062608012162000_10.9.e037961.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872-034X.2009.00507.x"},{"key":"2026062608012162000_10.9.e037961.13","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25731"},{"key":"2026062608012162000_10.9.e037961.14","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1111\/apt.13570","article-title":"Review article: bile acid diarrhoea - pathogenesis, diagnosis and management","volume":"43","author":"Mottacki","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"2026062608012162000_10.9.e037961.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61933-4"},{"key":"2026062608012162000_10.9.e037961.16","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X16656735"},{"key":"2026062608012162000_10.9.e037961.17","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1053\/j.gastro.2015.11.048","article-title":"Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography","volume":"150","author":"Imajo","year":"2016","journal-title":"Gastroenterology"},{"key":"2026062608012162000_10.9.e037961.18","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24376"},{"key":"2026062608012162000_10.9.e037961.19","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27678"},{"key":"2026062608012162000_10.9.e037961.20","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.01.038"},{"key":"2026062608012162000_10.9.e037961.21","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jhep.2016.06.005","article-title":"Mri and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice","volume":"65","author":"Dulai","year":"2016","journal-title":"J Hepatol"},{"key":"2026062608012162000_10.9.e037961.22","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejrad.2017.11.003","article-title":"Mr elastography is effective for the non-invasive evaluation of fibrosis and necroinflammatory activity in patients with nonalcoholic fatty liver disease","volume":"98","author":"Costa-Silva","year":"2018","journal-title":"Eur J Radiol"},{"key":"2026062608012162000_10.9.e037961.23","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.21751"},{"key":"2026062608012162000_10.9.e037961.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.10.015"},{"key":"2026062608012162000_10.9.e037961.25","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2A trial","volume":"392","author":"Sanyal","year":"2019","journal-title":"Lancet"},{"key":"2026062608012162000_10.9.e037961.26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30474-4"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-037961","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:04:00Z","timestamp":1782486240000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-037961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":26,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9,9]]},"published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1136\/bmjopen-2020-037961"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-037961","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9]]}}}